LUPIN-RIFAXIMIN DIN 02561549
Health Canada record
| Active ingredient(s) | RIFAXIMIN 550 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | A07AA11 RIFAXIMIN |
| Original market date | |
| Current status date | 01-Oct-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Lupin Pharma Canada Limited — licence 102119, currently licensed, last inspection rating C (2025-07-22).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing RIFAXIMIN
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02410702 | ZAXINE | SALIX PHARMACEUTICALS INC | Tablet | RIFAXIMIN 550 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36092 | 2025-10-01 | New Drug Submission (NDS) | Administrative: Licensing Agreement between two manufacturers |
International API supply for RIFAXIMIN
7 valid EDQM Certificates of Suitability from 7 holders. 23 active FDA Drug Master Files.
Request a quote for LUPIN-RIFAXIMIN